Brief: Allergy Therapeutics Commences Phase III Paediatric Trial
21/10/2024 07:29
Oct 21 (Reuters) - Allergy Therapeutics PLC AGY.L :
* COMMENCEMENT OF PHASE III PAEDIATRIC TRIAL
* PATIENT SCREENING UNDERWAY, DATA EXPECTED Q4 2025
Source text for Eikon: ID:nRSU8311Ia
Further company coverage: AGY.L
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Allergy Therapeutics
See all newsBrief: Allergy Therapeutics Expects FY 2026 Revenue Of £59.90 Million, Up 9% Reported
UK's Allergy Therapeutics FY revenue beats on Grassmuno launch
Allergy Therapeutics - Trading update for the year ended 30 June 2026
Brief: Allergy Therapeutics Appoints Helge Weiner-Trapness As Executive Chairman
Allergy Therapeutics - Appointment of Executive Chairman